Grassley on Monday released a letter from an attorney for Mylan saying officials would not testify. The Nov. 18 letter said company executives wouldn't testify because the settlement is a pending matter and the Justice Department would also not be attending.
Mylan will pay $465 million to settle allegations that it overbilled Medicaid for EpiPen. At issue was whether the product should have been classified as generic under a Medicaid program.
The list price of EpiPens had grown to $608 for a two-pack, an increase of more than 500 percent since 2007.
Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.